Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

Core Viewpoint - Arcadia Biosciences, Inc. has announced the immediate exercise of preferred investment options, significantly reducing the exercise price, which is expected to generate approximately $2.1 million in gross proceeds for the company [1][4]. Group 1: Investment Options and Financial Details - The company has entered into agreements to exercise outstanding preferred investment options for a total of 808,595 shares at a reduced exercise price of $2.575 per share [1]. - In exchange for the immediate exercise, Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares at an exercise price of $2.325 per share, which will be exercisable immediately [3]. - The offering is expected to close on or about January 12, 2026, subject to customary closing conditions, and the net proceeds will be used for working capital and general corporate purposes [4]. Group 2: Regulatory and Compliance Information - The new preferred investment options were offered in a private placement and have not been registered under the Securities Act of 1933, meaning they cannot be sold in the U.S. without proper registration or exemption [5]. - The company has committed to filing a registration statement with the SEC for the resale of shares issuable upon the exercise of the new preferred investment options [5]. Group 3: Company Background - Arcadia Biosciences has been innovating high-value, healthy ingredients since 2002, focusing on meeting consumer demands for healthier choices through agricultural innovation [7].